ESRD patients coinfected with human immunodeficiency virus and Hepatitis C: Outcomes and management challenges

Area of Science:

• Nephrology
• Infectious Diseases
• Transplantation

Background:

• Human Immunodeficiency Virus (HIV) infection is a significant global health concern.
• Shared transmission routes lead to frequent Hepatitis C Virus (HCV) coinfection in HIV-positive individuals.
• HIV/HCV coinfection exacerbates chronic kidney disease (CKD) and end-stage renal disease (ESRD) progression.

Purpose of the Study:

• To examine the impact of HIV/HCV coinfection on kidney disease progression and treatment outcomes.
• To evaluate the efficacy and safety of direct-acting antiviral agents in coinfected patients.
• To highlight critical drug-drug interactions for clinicians managing these complex patients.

Main Methods:

• Review of clinical data and outcomes in HIV/HCV coinfected patients.
• Analysis of survival rates on dialysis versus kidney transplantation.
• Assessment of post-transplant outcomes in coinfected individuals.
• Evaluation of drug-drug interactions between direct-acting antivirals, antiretroviral therapy, and immunosuppressants.

Main Results:

• HIV/HCV coinfection is associated with a higher burden of CKD and accelerated progression to ESRD.
• Dialysis survival is reduced in coinfected patients compared to those with HIV alone.
• Kidney transplant recipients with HIV/HCV coinfection experience inferior post-transplant outcomes.

Conclusions:

• HIV/HCV coinfection presents unique challenges in nephrology and transplantation.
• Direct-acting antiviral agents offer potential for improved survival but necessitate careful management of drug interactions.
• Clinicians must be vigilant regarding interactions between antivirals, antiretrovirals, and immunosuppressive therapies.